“Minimal Residual Disease” Is An Acceptable Accelerated Approval Endpoint In Multiple Myeloma, ODAC Says; FDA’s Withdrawal Authorities Make For Easy Vote

You must be a logged-in member of this site to view this article.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Alternatively, if your organization already has a license and you do not yet have an account, please click here to request access.